Louisiana State Employees Retirement System Buys New Shares in Amneal Pharmaceuticals, Inc. $AMRX

Louisiana State Employees Retirement System bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 75,300 shares of the company’s stock, valued at approximately $936,000.

Several other hedge funds have also recently added to or reduced their stakes in AMRX. Spire Wealth Management increased its holdings in shares of Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after buying an additional 1,023 shares in the last quarter. Intech Investment Management LLC grew its holdings in shares of Amneal Pharmaceuticals by 1.2% in the 4th quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock worth $1,229,000 after acquiring an additional 1,159 shares during the last quarter. Hsbc Holdings PLC raised its position in shares of Amneal Pharmaceuticals by 1.6% during the fourth quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after purchasing an additional 1,569 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Amneal Pharmaceuticals by 2.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after purchasing an additional 1,582 shares during the period. Finally, Comerica Bank lifted its holdings in shares of Amneal Pharmaceuticals by 56.1% during the fourth quarter. Comerica Bank now owns 4,690 shares of the company’s stock valued at $59,000 after purchasing an additional 1,685 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the transaction, the director owned 93,660 shares in the company, valued at approximately $1,211,960.40. This trade represents a 27.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 17.30% of the stock is currently owned by company insiders.

Amneal Pharmaceuticals Price Performance

AMRX opened at $17.15 on Monday. The company has a market capitalization of $5.47 billion, a PE ratio of 45.13 and a beta of 1.26. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $7.66 and a fifty-two week high of $17.86. The business has a 50-day moving average of $14.21 and a 200-day moving average of $13.58.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. The business had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. On average, equities research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on AMRX. Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, May 26th. Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. UBS Group initiated coverage on shares of Amneal Pharmaceuticals in a report on Friday, April 17th. They issued a “buy” rating and a $19.00 target price for the company. Wall Street Zen downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 29th. Finally, Barclays boosted their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $15.80.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.